Arlocabtagene autoleucel CAR T therapy for multiple myeloma that returned or resisted treatment
Tests arlocabtagene autoleucel in adults with relapsed or refractory multiple myeloma.
Plain-language title generated from the registry record
Registry title: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Calgary and Montreal, CanadaSee the 2 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding after several earlier treatments. It tests a CAR T cell therapy called Arlocabtagene Autoleucel (BMS-986393).
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Multiple myeloma that got worse during or after the last treatment, with disease that can be measured at screening. Physical fitness score (ECOG) of 0 or 1.
- Earlier treatment
- At least 4 classes of myeloma treatment, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), an anti-CD38 antibody and an anti-BCMA therapy, and at least 3 earlier lines of therapy. No earlier therapy aimed at GPRC5D.
Main reasons for not taking part
- Myeloma in the central nervous system, now or in the past
- Active infection despite proper treatment when blood cells are collected (leukapheresis)
- Severe infection, severe sepsis or bacteremia in the 28 days before leukapheresis
- Earlier therapy aimed at GPRC5D
- Other myeloma treatment without the required washout before leukapheresis
Read by machine on 9 November 2026.
Where in Canada
- Arthur J.E. Child Comprehensive Cancer CentreCalgary, CanadaTaking people
- McGill University Health CentreMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Trial code
- NCT06297226
- Record updated
- 6 October 2026
- Original description
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.Read full original descriptionShow less
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Inclusion: Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria; Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior lines of therapy (LOT); Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria; Participants must have measurable disease during screening; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion: Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Participants with severe infection, severe sepsis or bacteremia in the last 28 days prior to leukapheresis are excluded; Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis; Active or history of central nervous system involvement with MM; Other protocol-defined Inclusion/Exclusion criteria apply.